Abstract Body

Recognizing that suboptimal adherence is the major cause of treatment failure and lack of effectiveness of ARVs for PrEP, scalable interventions to improve adherence are badly needed. However, there are multiple patterns of suboptimal adherence and an understanding of the definitions and taxonomy of adherence is essential in designing interventions (Vrijens et al., Br J Clin Pharmacol. 2012; 73:691-705) Many interventions have been proposed, but to date none have been scalable and sustainable (Medication Adherence Interventions, Evidence Report No. 208. AHRQ Publication No.12-E010-EF, 2012). A limitation of most studies is the absence of reliable measures of adherence before and after an intervention. Moreover, the duration of benefit in those studies showing some increase in adherence dissipates over several months. What is needed is a scalable approach to identifying suboptimal adherence, monitoring those more likely to continue or become poorly adherent due to known predisposing factors, then focusing interventions on that cohort of patients. Due to the correspondence of drug exposure to loss of efficacy or protection from infection, sparse sampling of dosing information is insufficient, and detailed dosing information itself, shared with the patient and the provider, can significantly improve adherence. Modern technology allows detailed dosing histories to be obtained unobtrusively and collected centrally at a point in time when interventions can be applied. Combined with approaches such as Managed Problem Solving (Gross et al., JAMA Intern Med. 2013; 173:300-306) and Lifetime HIV Antiretroviral Therapy Adherence Intervention: Timing Is Everything (Bangsberg and Haberer, JAMA Intern Med. 2013; 173:306-7), progress towards scaling interventions towards populations at high risk for suboptimal adherence is now within reach.